Literature DB >> 30285213

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

A Vogel1, A Cervantes2, I Chau3, B Daniele4, J M Llovet5,6,7, T Meyer8,9, J-C Nault10, U Neumann11, J Ricke12, B Sangro13, P Schirmacher14, C Verslype15, C J Zech16, D Arnold17, E Martinelli18.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30285213     DOI： 10.1093/annonc/mdy308

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  193 in total

1.  The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT.

Authors:  Manuel de la Torre-Aláez; Carlota Jordán-Iborra; Andrea Casadei-Gardini; José Ignacio Bilbao; Macarena Rodriguez-Fraile; Lidia Sancho; Delia D'Avola; José Ignacio Herrero; Mercedes Iñarrairaegui; Bruno Sangro
Journal:  Cardiovasc Intervent Radiol       Date:  2020-03-12       Impact factor: 2.740

Review 2.  Hepatocellular carcinoma in older adults: A comprehensive review by Young International Society of Geriatric Oncology.

Authors:  Sukeshi Patel Arora; Gabor Liposits; Susan Caird; Richard F Dunne; Gordon Taylor Moffat; David Okonji; Maria Grazia Rodriquenz; Divyanshu Dua; Efrat Dotan
Journal:  J Geriatr Oncol       Date:  2019-11-06       Impact factor: 3.599

Review 3.  Cabozantinib: A Review in Advanced Hepatocellular Carcinoma.

Authors:  Emma D Deeks
Journal:  Target Oncol       Date:  2019-02       Impact factor: 4.493

4.  Application of ultrasound combined with enhanced MRI by Gd-BOPTA in diagnosing hepatocellular carcinoma.

Authors:  Shuwen Ji; Ziyong Wang; Shiyong Xia
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

Review 5.  [Locoregional and local ablative treatment options for liver tumors].

Authors:  J B Hinrichs; F K Wacker
Journal:  Internist (Berl)       Date:  2020-02       Impact factor: 0.743

Review 6.  Current locoregional therapies and treatment strategies in hepatocellular carcinoma.

Authors:  L Cardarelli-Leite; A Hadjivassiliou; D Klass; J Chung; S G F Ho; H J Lim; P T W Kim; A Mujoomdar; D M Liu
Journal:  Curr Oncol       Date:  2020-11-01       Impact factor: 3.677

Review 7.  Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome.

Authors:  Ziying Zhang; Haosheng Tang; Peng Chen; Hui Xie; Yongguang Tao
Journal:  Signal Transduct Target Ther       Date:  2019-10-12

8.  Regional liver function analysis with gadoxetic acid-enhanced MRI and virtual hepatectomy: prediction of postoperative short-term outcomes for HCC.

Authors:  Mengqi Huang; Shunli Shen; Huasong Cai; Zhenpeng Peng; Wan Hang Keith Chiu; Zi-Ping Li; Baogang Peng; Shi-Ting Feng
Journal:  Eur Radiol       Date:  2021-01-15       Impact factor: 5.315

9.  Alpha-fetoprotein response at different time-points is associated with efficacy of nivolumab monotherapy for unresectable hepatocellular carcinoma.

Authors:  Wei Teng; Chen-Chun Lin; Ming-Mo Ho; Kar-Wai Lui; Sheng-Fu Wang; Chao-Wei Hsu; Shi-Ming Lin
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

10.  Choledocho-nodal Fistula: Uncommon Cause of Obstructive Jaundice in a Patient with HCC Diagnosed by Combined ERCP/EUS.

Authors:  Mohamed H Emara; Mariam S Zaghloul; Aya M Mahros; Emad H Ema
Journal:  J Clin Imaging Sci       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.